There is also a phase I/II study to evaluate the safety and efficacy of CD38 CAR-T therapy in CD19-negative ALL patients, particularly in ALL patients treated with CD19 CAR-T cells (NCT04016129). This evidence concerns the gene CD38 and acute lymphoblastic leukemia.